A pragmatic approach to developing rare disease drug

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

whitePaper | November 25, 2022

Satyendra Sinha is a Functional Consultant with the TCS Life Sciences unit, and focuses on order management, distribution.

whitePaper | February 24, 2023

A new way of thinking and working has evolved for the discovery of therapeutic antibodies. Until recently, large numbers of antibodies were generated, only for a relatively small fraction to be sampled and engineered for further lead generation.